WCM Investment Management LLC Has $6.35 Million Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

WCM Investment Management LLC boosted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 58.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 154,664 shares of the company's stock after purchasing an additional 57,122 shares during the period. WCM Investment Management LLC owned about 0.52% of Keros Therapeutics worth $6,349,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Keros Therapeutics by 4.0% in the second quarter. BlackRock Inc. now owns 1,744,397 shares of the company's stock worth $70,090,000 after purchasing an additional 67,137 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Keros Therapeutics by 18.8% in the third quarter. Vanguard Group Inc. now owns 1,406,431 shares of the company's stock worth $44,837,000 after purchasing an additional 222,652 shares in the last quarter. Braidwell LP increased its stake in shares of Keros Therapeutics by 18.7% in the third quarter. Braidwell LP now owns 1,357,309 shares of the company's stock worth $43,271,000 after purchasing an additional 213,444 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Keros Therapeutics by 85.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,152,516 shares of the company's stock worth $49,213,000 after purchasing an additional 531,327 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Keros Therapeutics by 7.6% in the second quarter. State Street Corp now owns 1,015,903 shares of the company's stock worth $40,819,000 after purchasing an additional 71,744 shares in the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Down 5.3 %

KROS traded down $3.29 on Friday, reaching $58.61. 331,782 shares of the company traded hands, compared to its average volume of 338,227. Keros Therapeutics, Inc. has a one year low of $27.02 and a one year high of $73.00. The firm has a fifty day simple moving average of $63.22 and a two-hundred day simple moving average of $46.27. The company has a market cap of $2.11 billion, a P/E ratio of -11.27 and a beta of 1.26.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Friday, March 1st. The company reported ($1.34) EPS for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The business had revenue of $0.14 million for the quarter. During the same quarter last year, the business earned ($1.09) earnings per share. On average, equities analysts forecast that Keros Therapeutics, Inc. will post -5.11 earnings per share for the current year.

Wall Street Analyst Weigh In

KROS has been the subject of several research analyst reports. Truist Financial reaffirmed a "buy" rating and set a $100.00 target price on shares of Keros Therapeutics in a research note on Wednesday, March 13th. William Blair reissued an "outperform" rating on shares of Keros Therapeutics in a research note on Wednesday, February 21st. Piper Sandler reissued an "overweight" rating and issued a $105.00 price objective on shares of Keros Therapeutics in a research note on Wednesday, March 27th. Wedbush reissued an "outperform" rating and issued a $86.00 price objective on shares of Keros Therapeutics in a research note on Thursday, February 29th. Finally, HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Friday, March 1st. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $86.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.